Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

429
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
429
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

653
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
653
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

905
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
905
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

515
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
515
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

388
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
388

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The J-shape of β2GPI reveals a cryptic discontinuous epitope across domains I and II.

Journal of structural biology: X·2025
Same author

An open source in silico workflow to assist in the design of fusion proteins.

Computational biology and chemistry·2024
Same author

Poly-glutamic dendrimer-based conjugates for cancer vaccination - a computational design for targeted delivery of antigens.

Journal of drug targeting·2017
Same author

N-terminal or signal peptide sequence engineering prevents truncation of human monoclonal antibody light chains.

Biotechnology and bioengineering·2017
Same author

Impact of cofactor-binding loop mutations on thermotolerance and activity of E. coli transketolase.

Enzyme and microbial technology·2016
Same author

Antagonistic effects of indoloquinazoline alkaloids on antimycobacterial activity of evocarpine.

Journal of applied microbiology·2015

Related Experiment Video

Updated: Jun 1, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K

Inter-Domain interactions Slow BoNT/A's onset of action.

C J Lalaurie1, M Zloh2, D R Higazi3

  • 1Department of Biochemical Engineering, University College London, London, United Kingdom.

Journal of Structural Biology
|January 21, 2025
PubMed
Summary

Botulinum neurotoxin (BoNT) serotypes A and E exhibit different action speeds due to structural variations. BoNT/A shows slower activity onset than BoNT/E, linked to specific molecular dynamics and conformational changes at acidic pH.

More Related Videos

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K

Related Experiment Videos

Last Updated: Jun 1, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

4.9K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

13.6K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Structural Biology

Background:

  • Botulinum neurotoxin (BoNT) serotypes A and E share high sequence identity but differ in properties, notably onset of action.
  • BoNT/E exhibits a faster onset than BoNT/A, hypothesized to stem from distinct conformational arrangements.
  • The light chain (LC) and binding domain (BD) positioning relative to the translocation domain (TD) varies between serotypes.

Purpose of the Study:

  • To investigate the structural basis for the differing properties and action speeds of BoNT/A and BoNT/E.
  • To compare the biophysical characteristics of BoNT/A with existing data for BoNT/E.

Main Methods:

  • Molecular dynamics (MD) simulations were performed on BoNT/A across a range of pH values (4.5-5.5).
  • Circular dichroism (CD) spectroscopy was used to assess changes in protein secondary structure.
  • Small-angle X-ray scattering (SAXS) provided insights into the overall molecular shape and domain organization.

Main Results:

  • MD simulations revealed a loss of interactions between the switch region and the BD in BoNT/A at pH 5 and 5.5, suggesting increased flexibility.
  • CD spectroscopy indicated a gradual loss of helicity in BoNT/A below pH 5.5, stabilizing at pH 4.5.
  • Limited structural changes were observed in the key switch region of BoNT/A during MD simulations, contrasting with BoNT/E.

Conclusions:

  • The observed structural dynamics and limited flexibility in BoNT/A's switch region at acidic pH may explain its slower onset of action compared to BoNT/E.
  • Conformational differences, particularly in domain interactions and flexibility, are critical determinants of BoNT serotype activity.
  • This study provides a structural explanation for the differential kinetics of BoNT serotypes A and E.